Comparison of two injectable anesthetic drugs for the benefits of patients in modified electroconvulsive therapy(ECT)
Not Applicable
Completed
- Conditions
- Health Condition 1: null- ASA GRADE I AND IIHealth Condition 2: M511- Thoracic, thoracolumbar and lumbosacral intervertebral disc disorders with radiculopathy
- Registration Number
- CTRI/2018/03/012341
- Lead Sponsor
- Girish Kumar Singh
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
1.Age 18-65 years of either sex undergoing modified electroconvulsive therapy(ECT)
2.ASA grade I & II
Exclusion Criteria
1.Refusal of patient or relatives.
2.Allergy to trial drugs.
3.Major illness like T.B., asthma, neuromuscular disorders, respiratory disorders, hypertension, epilepsy, cardiovascular diseases, diabetes, history of MI in last six months.
•Patient on drugs which may alter the hemodynamic parameters.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method In Patients undergoing modified ECT, ketofol provides lesser induction time, better hemodynamic stability, longer mean seizure duration, earlier and smooth recovery as compared to propofol. further research with ketofol in modified ECT is warrantedTimepoint: september 2016 to september 2017
- Secondary Outcome Measures
Name Time Method Ketofol is better inducing agent then propofol in modified ECTTimepoint: One Year